Skip to main content
Erschienen in: Journal of Radiation Oncology 3-4/2020

30.07.2020 | Original Research

Peer review program to enhance treatment planning quality assurance for community radiation oncologists

verfasst von: Jessica Schuster, Greg Cooley, Benjamin Y. Durkee, Anna K. Olson, Adam R. Burr, Paul M. Harari

Erschienen in: Journal of Radiation Oncology | Ausgabe 3-4/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

Many cancer patients are treated at treatment centers staffed by community radiation oncologists (CRO). Patients choose these facilities for location convenience and anticipate equivalent care to “high volume” centers despite contrary literature. Local CROs hypothesized that a two-step quality assurance (QA) program that added early contour and case review would improve confidence in radiation treatment plan quality and reduce variability across facilities.

Methods

Five physicians at five academic satellites participated in the pilot two-step QA program. This program established an efficient, secure, HIPPA compliant workflow to review case details and contours on CT simulation after uploading to a remote access server on a commercially available platform.

Results

Over 12 months, 148 patient contours were reviewed by at least one CRO with an average of 2 reviewers per case. Reviewers approved 67% without change, requested clarification or change in 28%, and would not approve 4% of cases unless revised. The most common reasons cited for change request were “review GTV—volume increase” and “review CTV—volume increase.” Eighty-eight percent of treated cases that were not approved initially subsequently completed recommended modifications. Published literature was shared for 29% cases and sub-specialist consulted for 19% of cases.

Conclusion

A two-step QA program was considered highly valuable by all participants allowing easily implanted mechanisms for standardization, higher case volume, and shared educational resources for small academic satellite CROs who are faced with the challenge of caring for a diverse community cancer population. Feasibility suggests the model could serve as a model for other CRO.
Literatur
1.
Zurück zum Zitat Pohar S, Fung CY, Hopkins S, Miller R, Azawi S, Arnone A, Patton C, Olsen C (2013) American Society for Radiation Oncology (ASTRO) 2012 Workforce Study: the radiation oncologists’ and residents’ perspectives. Int J Radiat Oncol Biol Phys 87:1135–1140CrossRef Pohar S, Fung CY, Hopkins S, Miller R, Azawi S, Arnone A, Patton C, Olsen C (2013) American Society for Radiation Oncology (ASTRO) 2012 Workforce Study: the radiation oncologists’ and residents’ perspectives. Int J Radiat Oncol Biol Phys 87:1135–1140CrossRef
2.
Zurück zum Zitat Thompson SC, Cheetham S, Baxi S (2017) The enablers, barriers and preferences of accessing radiation therapy facilities in the rural developed world - a systematic review. BMC Cancer 17:794CrossRef Thompson SC, Cheetham S, Baxi S (2017) The enablers, barriers and preferences of accessing radiation therapy facilities in the rural developed world - a systematic review. BMC Cancer 17:794CrossRef
3.
Zurück zum Zitat Lin CC, Bruinooge SS, Kirkwood MK, Hershman DL, Jemal A, Guadagnolo BA, Yu JB, Hopkins S, Goldstein M, Bajorin D, Giordano SH, Kosty M, Arnone A, Hanley A, Stevens S, Olsen C (2016) Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 94:719–728CrossRef Lin CC, Bruinooge SS, Kirkwood MK, Hershman DL, Jemal A, Guadagnolo BA, Yu JB, Hopkins S, Goldstein M, Bajorin D, Giordano SH, Kosty M, Arnone A, Hanley A, Stevens S, Olsen C (2016) Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 94:719–728CrossRef
4.
Zurück zum Zitat Thaker NG, Sturdevant L, Jhingran A, Das P, Delclos ME, Gunn GB, McAleer MF, Tereffe W, Choi SL, Frank SJ, Simeone WJ Jr, Martinez W, Hahn SM, Famiglietti R, Kuban DA (2016) Assessing the quality of a radiation oncology case-based, peer-review program in an integrated academic and community cancer center network. J Oncol Pract 12:e476–e486CrossRef Thaker NG, Sturdevant L, Jhingran A, Das P, Delclos ME, Gunn GB, McAleer MF, Tereffe W, Choi SL, Frank SJ, Simeone WJ Jr, Martinez W, Hahn SM, Famiglietti R, Kuban DA (2016) Assessing the quality of a radiation oncology case-based, peer-review program in an integrated academic and community cancer center network. J Oncol Pract 12:e476–e486CrossRef
5.
Zurück zum Zitat Fairchild A, Straube W, Laurie F, Followill D (2013) Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys 87:246–260CrossRef Fairchild A, Straube W, Laurie F, Followill D (2013) Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys 87:246–260CrossRef
6.
Zurück zum Zitat Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN (2013) Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 105:387–393CrossRef Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN (2013) Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 105:387–393CrossRef
7.
Zurück zum Zitat Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, le QT, Gillison ML (2015) Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33:156–164CrossRef Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, le QT, Gillison ML (2015) Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33:156–164CrossRef
8.
Zurück zum Zitat Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D (2010) Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 28:2996–3001CrossRef Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D (2010) Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 28:2996–3001CrossRef
9.
Zurück zum Zitat Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S (2018) Radiation therapy quality assurance (RTQA) of concurrent chemoradiation therapy for locally advanced non-small cell lung cancer in the PROCLAIM phase 3 trial. Int J Radiat Oncol Biol Phys 101:927–934CrossRef Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S (2018) Radiation therapy quality assurance (RTQA) of concurrent chemoradiation therapy for locally advanced non-small cell lung cancer in the PROCLAIM phase 3 trial. Int J Radiat Oncol Biol Phys 101:927–934CrossRef
10.
Zurück zum Zitat Fairchild A, Aird E, Fenton PA, Gregoire V, Gulyban A, Lacombe D, Matzinger O, Poortmans P, Ruyskart P, Weber DC, Hurkmans CW (2012) EORTC radiation oncology group quality assurance platform: establishment of a digital central review facility. Radiother Oncol 103:279–286CrossRef Fairchild A, Aird E, Fenton PA, Gregoire V, Gulyban A, Lacombe D, Matzinger O, Poortmans P, Ruyskart P, Weber DC, Hurkmans CW (2012) EORTC radiation oncology group quality assurance platform: establishment of a digital central review facility. Radiother Oncol 103:279–286CrossRef
11.
Zurück zum Zitat Weber DC, Tomsej M, Melidis C, Hurkmans CW (2012) QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 105:4–8CrossRef Weber DC, Tomsej M, Melidis C, Hurkmans CW (2012) QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 105:4–8CrossRef
12.
Zurück zum Zitat Marks LB, Adams RD, Pawlicki T, Blumberg AL, Hoopes D, Brundage MD, Fraass BA (2013) Enhancing the role of case-oriented peer review to improve quality and safety in radiation oncology: executive summary. Pract Radiat Oncol 3:149–156CrossRef Marks LB, Adams RD, Pawlicki T, Blumberg AL, Hoopes D, Brundage MD, Fraass BA (2013) Enhancing the role of case-oriented peer review to improve quality and safety in radiation oncology: executive summary. Pract Radiat Oncol 3:149–156CrossRef
13.
Zurück zum Zitat Lawrence YR, Whiton MA, Symon Z, Wuthrick EJ, Doyle L, Harrison AS, Dicker AP (2012) Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. Int J Radiat Oncol Biol Phys 84:590–595CrossRef Lawrence YR, Whiton MA, Symon Z, Wuthrick EJ, Doyle L, Harrison AS, Dicker AP (2012) Quality assurance peer review chart rounds in 2011: a survey of academic institutions in the United States. Int J Radiat Oncol Biol Phys 84:590–595CrossRef
14.
Zurück zum Zitat Maguire PD, Honaker G, Neal C, Meyerson M, Morris D, Rosenman J, Tepper J (2007) A bridge between academic and community radiation oncology treatment planning. J Oncol Pract 3:238–241CrossRef Maguire PD, Honaker G, Neal C, Meyerson M, Morris D, Rosenman J, Tepper J (2007) A bridge between academic and community radiation oncology treatment planning. J Oncol Pract 3:238–241CrossRef
15.
Zurück zum Zitat Eaton BR, Pugh SL, Bradley JD, Masters G, Kavadi VS, Narayan S, Nedzi L, Robinson C, Wynn RB, Koprowski C, Johnson DW, Meng J, Curran WJ (2016) Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG oncology radiation therapy oncology group (RTOG) 0617. J Natl Cancer Inst 108 Eaton BR, Pugh SL, Bradley JD, Masters G, Kavadi VS, Narayan S, Nedzi L, Robinson C, Wynn RB, Koprowski C, Johnson DW, Meng J, Curran WJ (2016) Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG oncology radiation therapy oncology group (RTOG) 0617. J Natl Cancer Inst 108
16.
Zurück zum Zitat Lin SM, Ku HY, Chang TC, Liu TW, Chang CS, Hong JH (2018) Outcomes for cervical Cancer patients treated with radiation in high-volume and low-volume hospitals. Int J Radiat Oncol Biol Phys 102:184–193CrossRef Lin SM, Ku HY, Chang TC, Liu TW, Chang CS, Hong JH (2018) Outcomes for cervical Cancer patients treated with radiation in high-volume and low-volume hospitals. Int J Radiat Oncol Biol Phys 102:184–193CrossRef
17.
Zurück zum Zitat Gebhardt BJ, Thomas J, Horne ZD, Champ CE, Ahrendt GM, Diego E, Heron DE, Beriwal S (2018) Standardization of nodal radiation therapy through changes to a breast cancer clinical pathway throughout a large, integrated cancer center network. Pract Radiat Oncol 8:4–12CrossRef Gebhardt BJ, Thomas J, Horne ZD, Champ CE, Ahrendt GM, Diego E, Heron DE, Beriwal S (2018) Standardization of nodal radiation therapy through changes to a breast cancer clinical pathway throughout a large, integrated cancer center network. Pract Radiat Oncol 8:4–12CrossRef
18.
Zurück zum Zitat Karukonda P, Gebhardt BJ, Horne ZD, Heron DE, Beriwal S (2017) Standardization of radiation therapy dose for locally advanced non-small cell lung cancer through changes to a lung cancer clinical pathway in a large, integrated comprehensive cancer center network. Pract Radiat Oncol 7:e551–e5e7CrossRef Karukonda P, Gebhardt BJ, Horne ZD, Heron DE, Beriwal S (2017) Standardization of radiation therapy dose for locally advanced non-small cell lung cancer through changes to a lung cancer clinical pathway in a large, integrated comprehensive cancer center network. Pract Radiat Oncol 7:e551–e5e7CrossRef
19.
Zurück zum Zitat Gebhardt BJ, Heron DE, Beriwal S (2017) A peer review process as part of the implementation of clinical pathways in radiation oncology: does it improve compliance? Pract Radiat Oncol 7:332–338CrossRef Gebhardt BJ, Heron DE, Beriwal S (2017) A peer review process as part of the implementation of clinical pathways in radiation oncology: does it improve compliance? Pract Radiat Oncol 7:332–338CrossRef
20.
Zurück zum Zitat Brunskill K, Nguyen TK, Boldt RG, Louie AV, Warner A, Marks LB, Palma DA (2017) Does peer review of radiation plans affect clinical care? A systematic review of the literature. Int J Radiat Oncol Biol Phys 97:27–34CrossRef Brunskill K, Nguyen TK, Boldt RG, Louie AV, Warner A, Marks LB, Palma DA (2017) Does peer review of radiation plans affect clinical care? A systematic review of the literature. Int J Radiat Oncol Biol Phys 97:27–34CrossRef
21.
Zurück zum Zitat Mitchell JD, Chesnut TJ, Eastham DV, Demandante CN, Hoopes DJ (2017) Detailed prospective peer review in a community radiation oncology clinic. Pract Radiat Oncol 7:50–56CrossRef Mitchell JD, Chesnut TJ, Eastham DV, Demandante CN, Hoopes DJ (2017) Detailed prospective peer review in a community radiation oncology clinic. Pract Radiat Oncol 7:50–56CrossRef
22.
Zurück zum Zitat Ballo MT, Chronowski GM, Schlembach PJ, Bloom ES, Arzu IY, Kuban DA (2014) Prospective peer review quality assurance for outpatient radiation therapy. Pract Radiat Oncol 4:279–284CrossRef Ballo MT, Chronowski GM, Schlembach PJ, Bloom ES, Arzu IY, Kuban DA (2014) Prospective peer review quality assurance for outpatient radiation therapy. Pract Radiat Oncol 4:279–284CrossRef
23.
Zurück zum Zitat Boxer M, Forstner D, Kneebone A, Delaney G, Koh ES, Fuller M, Kaadan N (2009) Impact of a real-time peer review audit on patient management in a radiation oncology department. J Med Imaging Radiat Oncol 53:405–411CrossRef Boxer M, Forstner D, Kneebone A, Delaney G, Koh ES, Fuller M, Kaadan N (2009) Impact of a real-time peer review audit on patient management in a radiation oncology department. J Med Imaging Radiat Oncol 53:405–411CrossRef
24.
Zurück zum Zitat Rooney KP, McAleese J, Crockett C, Harney J, Eakin RL, Young VAL, Dunn MA, Johnston RE, Hanna GG (2015) The impact of colleague peer review on the radiotherapy treatment planning process in the radical treatment of lung cancer. Clin Oncol (R Coll Radiol) 27:514–518CrossRef Rooney KP, McAleese J, Crockett C, Harney J, Eakin RL, Young VAL, Dunn MA, Johnston RE, Hanna GG (2015) The impact of colleague peer review on the radiotherapy treatment planning process in the radical treatment of lung cancer. Clin Oncol (R Coll Radiol) 27:514–518CrossRef
25.
Zurück zum Zitat Rosenthal DI, Asper JA, Barker JL Jr et al (2006) Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck 28:967–973CrossRef Rosenthal DI, Asper JA, Barker JL Jr et al (2006) Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck 28:967–973CrossRef
26.
Zurück zum Zitat Cox BW, Kapur A, Sharma A, Lee L, Bloom B, Sharma R, Goode G, Potters L (2015) Prospective contouring rounds: a novel, high-impact tool for optimizing quality assurance. Pract Radiat Oncol 5:e431–e4e6CrossRef Cox BW, Kapur A, Sharma A, Lee L, Bloom B, Sharma R, Goode G, Potters L (2015) Prospective contouring rounds: a novel, high-impact tool for optimizing quality assurance. Pract Radiat Oncol 5:e431–e4e6CrossRef
Metadaten
Titel
Peer review program to enhance treatment planning quality assurance for community radiation oncologists
verfasst von
Jessica Schuster
Greg Cooley
Benjamin Y. Durkee
Anna K. Olson
Adam R. Burr
Paul M. Harari
Publikationsdatum
30.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 3-4/2020
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-020-00431-1

Weitere Artikel der Ausgabe 3-4/2020

Journal of Radiation Oncology 3-4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.